Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Clover Biopharmaceuticals Ltd.

Headquarters: Chengdu, China
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Joshua Liang
Number Of Employees: 387
Enterprise Value: $-10,564,066
PE Ratio: -0.32
Exchange/Ticker 1: HKEX:2197
Exchange/Ticker 2: N/A
Latest Market Cap: $39,160,784

BioCentury | Jun 16, 2023
Management Tracks

Arvinas’ Houston appointed chairperson

Plus: Berry joins Everest and updates from Avita and Vivoryon
BioCentury | Dec 20, 2022
Management Tracks

Nolan succeeding Session as CEO of Taysha 

Plus: Carmona named CFO at ADC, and updates from NewAmsterdam, CRISPR, Ikena, CN bio and more
BioCentury | Jul 1, 2022
Management Tracks

Vertex’s Hughes moves to Teva

Plus new CCO at Fate and updates from Nektar, Clover, ReviR and CARB-X
BioCentury | Apr 28, 2022
Management Tracks

Merck’s Garay to head commercial at Moderna

Plus Turtle leaving BridgeBio, and updates from Clover, Y-mAbs, Genenta and more
BioCentury | Apr 23, 2022
Product Development

COVID roundup: CureVac says low-dose bivalent vaccine effective in mice

Plus updates from Clover, Selva and ImmunoPrecise Antibodies
BioCentury | Feb 3, 2022
Management Tracks

New CMOs at Design, Mesoblast

Plus Loerop becomes CBO at Aclaris, updates from Clover, Kura, Fabric and more
BioCentury | Nov 5, 2021
Finance

Nov. 4 Quick Takes: Clover going public in Hong Kong at $2B valuation

Plus Mission BioCapital raises $275M early stage fund, PlateletBio, Evotec and more
Items per page:
1 - 7 of 7